Post-transcriptional regulation by microRNA-21 and let-7a microRNA in paediatric cholesteatoma

Journal of International Medical Research

Volumn 39, Issue 6, 2011, Pages 2110-2118

  Chen, X ^a   Qin, Z ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Adult; Child; Cholesteatoma; High mobility group AT hook 2 (HMGA2); Let 7 microRNA; MicroRNA 21; Phosphatase and tensin homologue (PTEN); Programmed cell death protein 4 (PDCD4)

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; LET 7A MICRORNA; MEMBRANE PROTEIN; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED CELL DEATH 4; RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER INVASION; CHOLESTEATOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CULTURE; SKIN EXAMINATION; TISSUE LEVEL; TRANSCRIPTION REGULATION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

EID: 84555206132     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900607     Document Type: Article

References (40)

1. James AL, Chadha NK, Papsin BC, et al: 5 Pediatric cholesteatoma and variants in the gene encoding connexin 26. Laryngoscope 2010; 120: 183-187.
2. Juhász A, Sziklai I, Rákosy Z, et al: Elevated level of tenascin and matrix metalloproteinase 6 9 correlates with the bone destruction capacity of cholesteatomas. Otol Neurotol 2009; 30: 559-565.
3. Kuczkowski J, Sakowicz-Burkiewicz M, Iz.ycka- ́wieszewska E, et al: Expression of tumour 7 necrosis factor-α, interleukin-1α, interleukin-6 and interleukin-10 in chronic otitis media with bone osteolysis. ORL J Otorhinolaryngol Relat Spec 2011; 73: 93-99.
4. Haruyama T, Furukawa M, Kusunoki T, et al: 8 Expression of IL-17 and its role in bone destruction in human middle ear cholesteatoma. ORL J Otorhinolaryngol Relat Spec 2010; 72: 325-331.
5. Suchozebrska-Jesionek D, Szymanski M, Kurzepa J, et al: Gelatinolytic activity of matrix metalloproteinases 2 and 9 in middle ear cholesteatoma. J Otolaryngol Head Neck Surg 2008; 37: 628-632.
6. Kuczkowski J, Kobierska-Gulida G, Izycka-Swieszewska E, et al: Molecular control of bone resorption in chronic otitis media with cholesteatoma. Otolaryngol Pol 2010; 64: 219-224 [in Polish, English abstract].
7. Kuczkowski J, Sakowicz-Burkiewicz M, Izycka-Swieszewska E: Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media. Am J Otolaryngol 2010; 31: 404-409.
8. Vitale RF, Pereira CS, Alves AL, et al: TNF-R2 expression in acquired middle ear cholesteatoma. Braz J Otorhinolaryngol 2011; 77: 531-536.
9. Bujía J, Holly A, Antolí-Candela F, et al: Immunobiological peculiarities of cholesteatoma in children: quantification of epithelial proliferation by MIB 1. Laryngoscope 1996; 106: 865-868.
10. Migirov L, Carmel E, Dagan E, et al: Mastoid subperiosteal abscess as a first sign of unnoticed cholesteatoma in children. Acta Paediatr 2010; 99: 147-149.
11. Kim JL, Jung HH: Proteomic analysis of cholesteatoma. Acta Otolaryngol 2004; 124: 783-788.
12. Kwon KH, Kim SJ, Kim HJ, et al: Analysis of gene expression profiles in cholesteatoma using oligonucleotide microarray. Acta Otolaryngol 2006; 126: 691-697.
13. Song JJ, Chae SW, Woo JS, et al: Differential expression of human beta defensin 2 and human beta defensin 3 in human middle ear cholesteatoma. Ann Otol Rhinol Laryngol 2007; 116: 235-240.
14. Ghanooni R, Decaestecker C, Simon P, et al: Characterization of patterns of expression of protein kinase C-α, -δ, -η, -γ and -ζ and their correlations to p53, galectin-3, the retinoic acid receptor-β and the macrophage migration inhibitory factor (MIF) in human cholesteatomas. Hear Res 2006; 214: 7-16.
15. Macias MP, Gerkin RD, Macias JD: Increased amphiregulin expression as a biomarker of cholesteatoma activity. Laryngoscope 2010; 120: 2258-2263.
16. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
17. Hui AB, Lenarduzzi M, Krushel T, et al: Comprehensive microRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 2010; 16: 1129-1139.
18. Djuranovic S, Nahvi A, Green R: A parsimonious model for gene regulation by miRNAs. Science 2011; 331: 550-553.
19. Nohata N, Sone Y, Hanazawa T, et al: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2011; 2: 29-44.
20. Gordanpour A, Stanimirovic A, Nam RK, et al: miR-221 is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer. Anticancer Res 2011; 31: 403-410.
21. Moriyama T, Ohuchida K, Mizumoto K, et al: MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009; 8: 1067-1074.
22. Hiyoshi Y Kamohara H, Karashima R, et al: MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 2009; 65: 1915-1922.
23. Fabjani G, Tong D, Wolf A, et al: HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep 2005; 14: 737-741.
24. Motoyama K, Inoue H, Nakamura Y, et al: Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 2008; 14: 2334-2340.
25. Friedland DR, Eernisse R, Erbe C, et al: Cholesteatoma growth and proliferation: posttranscriptional regulation by microRNA-21. Otol Neurotol 2009; 30: 998-1005.
26. Saj A, Lai EC: Control of microRNA biogenesis and transcription by cell signaling pathways. Curr Opin Genet Dev 2011; 21: 504-510.
27. Zhu S, Wu H, Wu F, et al: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008; 18: 350-359.
28. Meng F, Henson R, Wehbe-Janek H, et al: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-658.
29. Frankel LB, Christoffersen NR, Jacobsen A, et al: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008; 283: 1026-1033.
30. Edwin F, Singh R, Endersby R, et al: The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 2006; 281: 4816-4822.
31. Sayed D, Rane S, Lypowy J, et al: MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008; 19: 3272-3282.
32. Suzuki A, Nakano T, Mak TW, et al: Portrait of PTEN: messages from mutant mice. Cancer Sci 2008; 99: 209-213.
33. Johnson SM, Grosshans H, Shingara J, et al: RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647.
34. Mayr C, Hemann MT, Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007; 315: 1576-1579.
35. Park SM, Shell S, Radjabi AR, et al: Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007; 6: 2585-2590.
36. Wong TS, Man OY, Tsang CM, et al: MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J Cancer Res Clin Oncol 2011; 137: 415-422.
37. Fedele M, Battista S, Kenyon L, et al: Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002; 21: 3190-3198.
38. Qian ZR, Asa SL, Siomi H, et al: Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol 2009; 22: 431-441.
39. Johnson CD, Esquela-Kerscher A, Stefani G, et al: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67: 7713-7722.
40. Peng Y, Laser J, Shi G, et al: Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 2008; 6: 663-673.